Plasma activity of of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever

SONMEZ, Mehmet; AYDIN, Kemalettin; DURMUS, Ahmet; SUCU, Nurgul; YILMAZ, MUSTAFA; Akdogan, ELİF; KOKSAL, Iftihar; OVALI, Ercument; OMAY, Serdar

doi:10.1016/j.jinf.2007.02.010

Plasma activity of of thrombin activatable fibrinolysis inhibitor in Crimean-Congo hemorrhagic fever

SONMEZ M., AYDIN K., DURMUS A., SUCU N., YILMAZ M., Akdogan E., ...Daha Fazla

JOURNAL OF INFECTION, cilt.55, sa.2, ss.184-187, 2007 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 55 Sayı: 2
Basım Tarihi: 2007
Doi Numarası: 10.1016/j.jinf.2007.02.010
Dergi Adı: JOURNAL OF INFECTION
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.184-187
Recep Tayyip Erdoğan Üniversitesi Adresli: Hayır

Özet

Objectives: Crimean-Congo hemorrhagic fever (CCHF) is a potentially fatal viral infection. The exact mechanism for hemorrhage remains unknown. Thrombin activatable fibrinolysis inhibitor (TAFI) is a plasma procarboxypeptidase B-like proenzyme and synthesized in the liver, down-regulating fibrinolysis. In this study, we measured the TAR activity in plasma of patients with CCHF to examine the relationship between hemorrhage and the pathogenesis of CCHF.